WORKATO
5.5.2021 01:03:06 CEST | Business Wire | Press release
Workato , the leading enterprise automation platform, has today launched its first EMEA data centre in Frankfurt, Germany. The new data centre has been set up in response to exceptionally strong growth in the EMEA region, the company has seen a 289% increase in data usage on its platform from EMEA in the last 12 months. The launch of the data centre is part of the company’s strategy to boost investment twofold in the region and will provide Workato customers with a centralised location for hosting their data and provide assurance that their data residency requirements including GDPR are fully compliant and that their data is secure and protected.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504006038/en/
The opening of the data centre in Frankfurt is testament to the strong demand Workato is seeing from European enterprises for its integration-led automation.
Workato supports customers throughout EMEA with operations currently in Spain, UK, Germany, France, Ireland, Netherlands and Italy. In January this year, the company announced Series D funding worth $110 million to be used to invest in developing its technology and expanding product innovation to help more companies around the world transform the way they work. Workato’s current customer base comprises of companies from the tech, financial services and fintech, transport and logistics, ecommerce and retail industries and include TFG Transfracht (Deutsche Bahn Group), Box, World Economic Forum (WEF), Showpad, Jumia and WorldRemit. As part of the company’s mission to improve the way enterprises work, Workato forms strategic partnerships with organisations such as Deloitte.
Markus Zirn, SVP of Strategy & Business Development at Workato commented: “The pandemic saw digital transformation catapulted to the top priority for enterprises. With increased focus on digital strategies and remote working, EMEA enterprises quickly recognised the need for automation platforms like Workato to achieve automation at scale by easily, reliably, and securely connecting applications, data, and business processes so teams can work smarter and faster.”
He added: “In response to this very strong demand for our technology across EMEA, we have invested in this new data centre, serving our European customers to ensuring their data is held in full compliance with new EU-data regulations, eliminating any risk and allowing us to help more and more businesses within the EU transform the way they work. We are delighted to be investing in this very important region for Workato and to be expanding our operations in EMEA.”
Workato customer, Agatha Sick, Head of IT at TFG Transfracht said: "Workato is enabling us to automate workflows across our enterprise.” She continued, “We are excited about the launch of the data centre in Europe as this will provide us with the option to store our data in the EU and comply with the EU data protection regulations."
Mark Watson, Chief Technology Officer at WorldRemit , another Workato customer added: “Workato’s powerful low-code/no-code integration and automation platform is enabling us to achieve automation at scale. We are excited about the launch of Workato’s Data Center in the European Union as it will enable us to keep our data close to home.”
Workato allows companies to maximise the value of their apps, data and people by making it easy to integrate disconnected data and applications, and securely automate workflows to accelerate business outcomes. Workato’s no code/low code platform combines enterprise-grade integration and automation capabilities in a single platform that is trusted by IT and easy to use for the business. With Workato, IT and business teams can more easily collaborate to rapidly integrate data, processes, applications and user experiences in almost any combination without compromising security and governance.
About Workato
Workato is the leading Enterprise Automation Platform. Recognised as a leader, Workato is the only enterprise platform that enables both business and IT to integrate their apps, automate business workflows, and drive real time outcomes from business events, without compromising security and governance. Workato is trusted by over 7,000 of the world’s top brands and fastest growing innovators.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504006038/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom